HAYWARD,
Calif., Nov. 3, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company, today announced that it will
release third quarter financial results after market close
on Monday, November 14, 2022. Thereafter, AcelRx management
will host a live webcast and conference call at 4:30 p.m.
Eastern Daylight Time/1:30 p.m. Pacific
Daylight Time on November 14, 2022, to discuss the
financial results and provide an update on the Company's
business.
Webcast Information
The webcast can be accessed by visiting the "Investors" section
of the Company's website at www.acelrx.com and clicking
on the webcast link within the News & Events/Upcoming Events
section. The webcast will include a slide presentation and a replay
will be available on the AcelRx website for 90 days following the
event.
Conference Call Information
Investors who wish to participate in the conference call may do
so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657
for Canadian callers, or 1-412-902-4204 for international
callers. The conference ID is 10172773.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S., DSUVIA® (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include:
Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg),
an investigational product in the U.S. being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings; two pre-filled, ready-to-use syringes of ephedrine and
phenylephrine licensed for the U.S. from Aguettant; Niyad™, a
regional anticoagulant for the extracorporeal circuit; and LTX-608,
for the potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. DZUVEO and Zalviso are both approved products in
Europe.
This release is intended for investors only. For additional
information about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-third-quarter-2022-financial-results-call-and-webcast-on-november-14-2022-301667425.html
SOURCE AcelRx Pharmaceuticals, Inc.